tbuckley/cabot-search huggingface dataset:
Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD
Authors: Helgo Magnussen, Kay Tetzlaff, Eric D. Bateman, Henrik Watz, Anne M. Kirsten, Emiel F.M. Wouters, Bernd Disse, Helen Finnigan, Roberto Rodriguez-Roisin, Peter M.A. Calverley
Journal: European Respiratory Journal (2015)

The combination of an inhaled long-acting β2-agonist with an inhaled corticosteroid (ICS) is widely used in the management of chronic obstructive pulmonary disease (COPD), primarily to prevent exacerbations [1]. Concerns about the increased risk of pneumonia, even with newer ICS [2], have generated interest in whether the ICS can be safely withdrawn from patients with COPD. We recently reported, in the WISDOM (Withdrawal of inhaled steroids during optimized bronchodilator management) study ([clinicaltrials.gov][1] identifier number: [NCT00975195][2]), that patients who continued treatment with a long-acting β2-agonist plus a long-acting muscarinic antagonist did not have an increased risk of exacerbations [3]. However, we observed a statistically significant difference in forced expiratory volume in 1 s (FEV1) after complete ICS withdrawal and at the end of the study in favour of continued ICS treatment. Decreased FEV1 after complete ICS withdrawal in severe COPD was not progressive and did not predict clinical changes <http://ow.ly/TtYDV> Medical writing assistance was provided by Marshall Naden (Complete HealthVizion, Glasgow, UK), which was contracted and compensated by Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, Germany). [1]: https://clinicaltrials.gov [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00975195&atom=%2Ferj%2F47%2F2%2F651.atom
Epidemiology of nasopharyngeal carcinoma (NPC) in California: Survival advantage of Chinese WHO Type 1 NPC patients resulted in Asian ethnicity as an independent and favorable prognostic factor of survival for NPC patients as a whole and for patients with the WHO histologic type 1
Authors: S. I. Ou, J. A. Zell, A. Ziogas, H. Anton-Culver
Journal: Journal of Clinical Oncology (2006)

5514 Background: We have previously shown that Chinese race is an independent and favorable prognostic factor in NPC survival. We expanded our study to investigate whether Asian ethnicity has the same favorable survival characteristics and if there is a survival difference between Chinese and non-Chinese Asians. Methods: 1,657 newly diagnosed NPC patients from 1992 to 2002 were analysed from the population-based California Cancer Registry. Five year survival rate estimates and Kaplan-Meier curves were calculated. Cox proportional ratios were used to identify independent prognostic factor for survival. Results: The 5-year survival rate of Asian NPC patients was improved compared to non-Asian patients (62% vs 47%; P &lt; .0001). By multivariate analyses, early age of diagnosis, localized stage at presentation (vs distant, HR = 0.41; P &lt; .0001), WHO Type 3 histology (vs Type 1; HR = 0.64; P &lt; .0001), socio-economic status (highest vs lowest quartile; HR = 0.71; P = .0012), use of radiation (vs none; HR = 0.55; P &lt; .0001), and Asian ethnicity (vs Caucasian; HR = 0.82; P = .016) were associated with improved survival. Chinese composed the majority of the Asian ethnicity (49.1%) followed by Filipino (21.2%) and Vietnamese (14.9%). The 5-year survival rate of Chinese was better than non-Chinese Asians (67% vs 56%; P = .0005). When Asian ethnicity was analyzed separately as Chinese and non-Chinese, Chinese retained an overall favorable prognosis (HR = 0.72; P = .0016) whereas non-Chinese Asians did not (HR = 0.91; P = .34). Within each NPC WHO histologic type, early age of diagnosis, localized stage at presentation, and use of radiation were favorable prognostic factors. Chinese (HR = 0.62; P = .0006) but not non-Chinese Asian ethnicity (HR = 0.78; P = .053) was an additional favorable prognostic factor within WHO histologic Type 1. Conclusions: The significant survival advantage of Chinese WHO Type 1 NPC patients resulted in Asian ethnicity being an independent and favorable prognostic factor for survival in NPC. This observation may reflect underlying genetic difference among different racial groups with NPC WHO Type 1. No significant financial relationships to disclose.
Finerenone for Albuminuria in Patients With Diabetic Nephropathy—Reply
Authors: George L. Bakris, Christina Nowack
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in <i>RAS</i>-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial.
Authors: Pierre Laurent-Puig, Sophie Paget-Bailly, Dewi Vernerey, Celine Vazart, Virginie Decaulne, Karine Fontaine, Francis Rousseau, Faye Elliott, Philip Quirke, Susan Richman, Jenny Seligman, Matthew T. Seymour, Franck Bonnetain, Francois Liebaert, Raphaële Thiébaut
Journal: Journal of Clinical Oncology (2015)

3547 Background: miR 31 3p expression has previously shown correlation with outcomes in KRAS wild-type (wt) aCRC patients receiving EGFR-targeted therapy. We have therefore evaluated miR 31 3p in a large randomized trial of panitumumab. The a priori hypothesis was that pts with the lowest miR 31 3p expression would have better outcomes and increased benefit from panitumumab. Methods: miR 31 3p was measured in tumor from 213 pts randomized to irinotecan (Ir, n = 111) or irinotecan/panitumumab (IrPan, n = 102) in a trial of second line therapy for aCRC (PICCOLO). The analysis population comprised RAS wt (KRAS and NRAS wt) pts (n = 188: Ir = 101, IrPan-87). End-points were progression-free survival (PFS), overall survival (OS), complete/partial response rate (RR) and disease control rate (DCR). The predefined model divided pts into 3 tertiles with high, intermediate (int) and low miR 31 3p expression, and compared outcomes and treatment effects across these groups. Multivariate analysis was performed, adjusting for Köhne score. Results: In the prognostic analysis, compared with low expression pts and after adjustment for treatment arm, int and high pts had worse OS (HR 1.58, 2.03 respectively; p = 0.0012) and worse PFS (HR 1.60, 1.60 respectively; p = 0.018). In multivariate analysis, miR 31 3p and Köhne score were independently associated with OS (p = 0.0006 and p = 0.002 respectively). miR 31 3p was also significantly independently associated with RR (p = 0.015) and DCR (p = 0.074). In the predictive analysis, panitumumab produced marked PFS benefit in pts with low and int miR 31 3p expression (HR = 0.50 [p = 0.019] and HR = 0.57 [p = 0.031] respectively), but not in pts with high expression (HR 0.72, p = 0.23); however, a statistically significant treatment/expression interaction was not seen. Conclusions: Pts with lower miR 31 3p have significantly better OS, PFS, RR and DCR, independent of treatment. Pts with low/int miR 31 3p had significant PFS benefit from panitumumab whilst pts with high miR 31 3p did not; however this study was not powered to demonstrate a statistically significant treatment/expression interaction. miR-31-3p is a highly promising biomarker in aCRC.
Corrigendum to: “Genetic control of sodium channel function” [Cardiovascular Research 57 (2003) 961–973]⋆
Authors: H Tan
Journal: Cardiovascular Research (2003)

In the original article Figs. 2, 3 and 4 were incorrect. The correct figures are shown on the following pages.



Fig. 4 
(A) Representative electrocardiogram of isolated conduction disease (40 ms/div). Note marked QRS widening and PQ interval prolongation. (B) SCN5A mutations associated with isolated conduction …
Follow up in breast cancer
Authors: E. Grunfeld, P. Yudkin, R. Adewuyl-Dalton, M. P Vessey, D. Mant
Journal: BMJ (1995)

EDITOR,--John Dewar calls for a reappraisal of how women with breast cancer are followed up.1 We now have compelling evidence that intensive follow up does not improve either quality of life related to health or overall survival.2 3 In the light of this, Dewar wonders what the effect of routine follow up is on the patient, in terms of both quality of life and cost. He also wonders what the optimum follow up practice should be and calls for as rigorous an assessment of follow …
Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia
Authors: Ian Flinn, Manish Patel, Brad S. Kahl, Steven M. Horwitz, Francine M. Foss, Yasuhiro Oki, Pierluigi Porcu, Jennifer Sweeney, Kerstin Allen, Kerrie Faia, Patricia Harris, Joi Dunbar, Howard M. Stern, Patrick Kelly, Susan O'Brien
Journal: Blood (2013)
Pilot study of proton therapy for treatment of regional lymphatics in patients with breast cancer.
Authors: Julie Ann Bradley, Roi Dagan, Meng Wei Ho, Natalie Xu, Christopher G. Morris, Zuofeng Li, Nancy P. Mendenhall
Journal: Journal of Clinical Oncology (2013)

100 Background: To determine the feasibility of proton therapy (PT) for regional nodal irradiation (RNI) in women with breast cancer and to compare target coverage and normal tissue avoidance between PT and conventional radiation. Methods: From May 2012 to May 2013, 14 women were prospectively enrolled in this pilot study; 5 had right-sided and 9 had left-sided. Median age at the time of PT was 53.7 years (range 37-73). The breast or chest wall and supraclavicular, axillary, and internal mammary (IM) lymph nodes were treated in all patients. Proton and conventional plans were developed for each patient; the superior plan, as defined by organ at risk sparing and target coverage, was treated. Targets and normal tissues were delineated on treatment CT scans. Wilcoxon signed rank sum test was used to compare dose-volume parameters. Results: For all 14 patients, the proton plan better met the dosimetric goals, and was used for treatment delivery. Median heart V5 measured 0.8% for the proton plans versus 23% for the conventional plans (p=0.0005). Median mean heart dose measured 0.55 Gy (range 0– 3.2Gy) for the proton plans versus 4.9 Gy (range 2-9.1 Gy) for the conventional plans (p=0.0005). Significant difference in median lung V5 and median V20 were found: 41% and 24% for the proton plans and 67% and 38% for conventional plans, respectively. PTV breast/chest wall coverage was adequate with both plans. Coverage of the level II axilla was higher in the proton plans (D95 48 Gy vs 44 Gy, p=0.01) as was coverage of the IM nodes (D95 50 Gy vs 46 Gy, p=0.01). Acute toxicity data is available for 12 patients. The most common acute toxicity was radiation dermatitis, with 9 patients experiencing grade 2 and 3 patients experiencing grade 3 toxicity. Other grade 2 toxicities included fatigue (n=3), pain (n=2), esophagitis (n=4), and skin infection (n=1). Radiation dermatitis was the only grade 3 toxicity. No grade 4 or 5 toxicities developed. Conclusions: Adjuvant PT is a well-tolerated, technically feasible modality for RNI, with a significant decrease in cardiac V5, V20, and mean heart dose as well as lung V5 and V20. Further investigation of PT for RNI in breast cancer is warranted to improve the therapeutic ratio by decreasing radiation exposure to the heart and lung. Clinical trial information: NCT01365845.
School-Based Myopia Prevention Effort—Reply
Authors: Mingguang He, Ian G. Morgan
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Athletic Cardiac Remodeling in US Professional Basketball Players
Authors: David J. Engel, Allan Schwartz, Shunichi Homma
Journal: JAMA Cardiology (2016)

<h3>Importance</h3> The incidence of sudden cardiac death is higher in US basketball players compared with other athlete groups. However, the recognition of the risk for sudden cardiac death among basketball players is challenging because little is known regarding athletic cardiac remodeling in these athletes or athletes of similarly increased size. <h3>Objective</h3> To perform a comprehensive cardiac structural analysis of National Basketball Association (NBA) professional athletes. <h3>Design, Setting, and Participants</h3> Echocardiographic observational study of NBA players on the active rosters for the 2013-2014 and 2014-2015 seasons was performed from December 16, 2013, to December 12, 2014. The policy of the NBA mandates annual preseason stress echocardiograms for each player. The NBA has sanctioned Columbia University Medical Center to conduct annual health and safety reviews of these echocardiograms. Data were analyzed from January to May 2015. <h3>Main Outcomes and Measures</h3> Cardiac variables assessed included left ventricular (LV) size, mass, wall thickness, and hypertrophy patterns and function; left atrial volume; and aortic root diameter. All dimensions were biometrically scaled. <h3>Results</h3> Of the 526 athletes included in the study, 406 (77.2%) were African American and 107 (20.3%) were white, with a mean (SD) age of 25.7 (4.3) years. Mean (SD) athlete height was 200.2 (8.8) cm; mean body surface area, 2.38 (0.19) m<sup>2</sup>. Left ventricular size and mass in NBA athletes were proportional to body size, extending to the uppermost biometrics of the cohort. Left ventricular hypertrophy was present in 144 athletes (27.4%). African American athletes had increased LV wall thickness (unadjusted mean, 11.2 mm; 95% CI, 11.1-11.3 mm) and LV mass (unadjusted mean, 106.3 g/m<sup>2</sup>; 95% CI, 104.6-108.0 g/m<sup>2</sup>) compared with LV wall thickness (unadjusted mean, 10.5 mm; 95% CI, 10.3-10.7 mm;<i>P</i> &lt; .001) and LV mass (unadjusted mean, 102.2 g/m<sup>2</sup>; 95% CI, 99.0-105.4 g/m<sup>2</sup>;<i>P</i> = .029) in white athletes. The maximal aortic root diameter in the cohort was 42 mm. Aortic root diameters reached a plateau at the uppermost biometric variables. Five athletes (1.0%) had an LV ejection fraction of less than 50%, and all ventricles augmented normally with exercise. <h3>Conclusions and Relevance</h3> This study provides normative cardiac data for a group of athletes with greater anthropometry than any previously studied athlete group and for a group known to have elevated rates of sudden cardiac death. These data can be incorporated into clinical assessments for the primary prevention of cardiac emergencies in basketball players and the athletic community at large.
Nationwide outbreak of Salmonella enterica serotype 4,12:i:- infections in France, linked to dried pork sausage, March-May 2010
Authors: A Bone, H Noel, S Le Hello, N Pihier, C Danan, M E Raguenaud, S Salah, H Bellali, V Vaillant, F  X Weill, N Jourdan-da Silva
Journal: Eurosurveillance (2010)

In May 2010, a nationwide excess of infections with the specific monophasic variant Salmonella enterica serotype 4,12:i:- was investigated in France. Subtyping with multilocus variable number of tandem repeats analysis revealed a distinct epidemic strain within this excess. Epidemiological investigations identified a dried pork sausage sold by a particular chain of supermarkets as the likely vehicle of transmission. The suspected batches have been withdrawn and recalled.
Decreased interleukin-12 (IL-12) from activated cord versus adult peripheral blood mononuclear cells and upregulation of interferon- gamma, natural killer, and lymphokine-activated killer activity by IL- 12 in cord blood mononuclear cells
Authors: SM Lee, Y Suen, L Chang, V Bruner, J Qian, J Indes, E Knoppel, C van de Ven, MS Cairo
Journal: Blood (1996)
Opportunities for improved end-of-life (EOL) care for adult patients with advanced cancer: Results of a longitudinal assessment of care provided by Quality Oncology Practice Initiative (QOPI) participants.
Authors: David W. Dougherty, Pamela Kadlubek, Trang Pham, Craig Earle, Jennifer Malin, Larry Breathwaite, Joseph O. Jacobson
Journal: Journal of Clinical Oncology (2013)

9537 Background: End of life care of patients with advanced cancer has received recent attention because of evidence of widespread variation in utilization of aggressive therapies and interventions and possible suboptimal use of palliative care and hospice services. QOPI, the ASCO sponsored quality assessment program, has been available to all United States physician members since January 2006 and has assessed EOL care since its inception. The current analysis explores whether the increased national focus on EOL and increased availability of palliative care and hospice services has resulted in improvements in EOL care as reported by QOPI participants. Methods: Data was aggregated across all EOL care quality measures for 9 sequential semi-annual QOPI collection periods from 2008 through 2012. Trends were analyzed among rates of eligible patients related to hospice enrollment and timing of enrollment, palliative care referrals, discussions about hospice and palliative care, and chemotherapy administration at the end of life. The Cochran-Armitage trend test was performed to determine the significance of trends and differences in measure performance over time. Results: From Fall 2008 to Fall 2012, the rate of hospice enrollment for appropriate patients improved by 7.4% [51.8% to 59.2%; p&lt;0.0001] and the rate of hospice enrollment or palliative care referral improved by 5.6% [63.3% to 68.9%; p&lt;0.0001]. Modest improvements were seen in the rates of hospice enrollment more than 3 and 7 days before death [2.8%, 2.6%], discussion of hospice or palliative care with patients not referred for these services within the last 2 months of life [2.7% increase; 19% to 21.7%], and chemotherapy administration within the last 2 weeks of life [2.4% improvement from 13.7% to 11.3%]. Conclusions: Despite modest increases in the rate of hospice enrollment and palliative care referrals over time, EOL care for adult patients with cancer associated with QOPI practices remains suboptimal. Opportunities exist to increase more meaningful participation in hospice and palliative care and to reduce exposure to chemotherapy near death.
deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
Authors: Rachel Rosenthal, Nicholas McGranahan, Javier Herrero, Barry S. Taylor, Charles Swanton
Journal: Genome biology (2016)

Analysis of somatic mutations provides insight into the mutational processes that have shaped the cancer genome, but such analysis currently requires large cohorts. We develop deconstructSigs, which allows the identification of mutational signatures within a single tumor sample. Application of deconstructSigs identifies samples with DNA repair deficiencies and reveals distinct and dynamic mutational processes molding the cancer genome in esophageal adenocarcinoma compared to squamous cell carcinomas. deconstructSigs confers the ability to define mutational processes driven by environmental exposures, DNA repair abnormalities, and mutagenic processes in individual tumors with implications for precision cancer medicine.
Toll Like Receptors Have mRNA Differentiated Expression In Dendritic Cells In Crisis-State Sickle Cell Anemia Patients, Suggesting a Pivotal Role Of These Molecules and Cell Type In The Maintenance Of Inflammatory Response
Authors: Cyntia Cajado, Kyioshi Ferreira Fukutani, Wendell Vilas Boas, Bruno Antônio Veloso Cerqueira, Natalia Machado Tavares, Ivana Leite, Isadora Siqueira, Isa Lyra, Elisangela Adorno, Marilda Souza Goncalves
Journal: Blood (2013)
Chemotherapy-naïve cancer patients’ expectations of developing treatment-related side effects: A URCC CCOP study of 670 patients from community practices
Authors: M. Hofman, G. R. Morrow, S. L. Ranson, P. Jean-Pierre, S. R. Dakhil, T. Moore, J. Atkins
Journal: Journal of Clinical Oncology (2006)

8509 Background: Adequate management of cancer related side effects is important for patients yet challenging for clinical staff. Cancer treatment side effects have been characterized reasonably well in the literature; however, less is known about the relationships among response expectancies, personal characteristics, and side effects development of chemotherapy-naïve patients undergoing doxorubicin treatments. Methods: The present sample included 701 cancer patients from 14 CCOP institutions affiliated with the URCC CCOP research base. Of the total sample, 670 patients provided evaluable data to an item that assessed expectations that they will develop side effects such as nausea, vomiting, fatigue, and hair loss. Patients indicated their expectations on a 5-point scale (from 1 = “I am certain I will NOT have this” to 5 = “I am certain I WILL have this”). Results: The median number of symptoms expected (any value other than 1) was 4. Hair loss was most expected (98%) and vomiting the least (87%). Older patients (&gt; 53-years, N = 316, ) were less confident they would get nausea (M old = 2.96, SE = 0.064; M young = 3.23, SE = 0.057, p &lt; 0.01) and hair loss (M old = 4.22, SD = 0.063; M young = 4.39, SE = 0.051, p &lt; 0.05). Females (n = 633) were more confident they would get hair loss than males (M female = 4.34, SE = 0.041; M male = 3.89, SE = 0.172, p &lt; 0.05). Patients who had some college (n = 397) thought it was more likely they would get hair loss than patients with less education (M college = 4.38, SE = 0.048; M nocollege = 4.21, SE = 0.069, p &lt; 0.05). Conclusions: Chemotherapy-naïve patients scheduled to take doxorubicin clearly exhibit expectations about treatment side effects, which are influenced by age, gender and education. The findings show that knowledge of patients’ response expectancies and personal characteristics should be considered and integrated into interventions to control treatment side effects. Supported, in part, by a supplement from the Division of Cancer Control and Population Sciences, NCI, to Public Health Service grant U10 CA37420 and by grant RSG-01-071-PBP from the ACS [Table: see text] No significant financial relationships to disclose.